ScreenerHero

STTK Shattuck Labs, Inc.

NAS · US · Healthcare · Biotechnology · shattucklabs.com
5.655USD-3.50%Mkt Cap: 567.55M $P/E: —

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a de…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap567.55M USD
Enterprise Value382.50M USD
Revenue (TTM)1.00M USD
Gross Profit-38.24M USD
Net Income (TTM)-48.81M USD
Revenue/Share0.01 USD
Last Price5.655 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees40
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.02
PEG—
EV/EBITDA-7.34
EV/Revenue382.50
P/S588.13
P/B2.80
EPS (TTM)-0.47
EPS (Forward)-0.53
52W Range
1.70060% of range8.330
52W High8.330 USD
52W Low1.700 USD
Profitability
Gross Margin0.00%
Oper. Margin-5570.50%
EBITDA Margin0.00%
Profit Margin-4880.90%
ROE-59.24%
ROA-53.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.88M USD
CapEx (TTM)71.00K USD
FCF Margin-2121.66%
FCF Yield-3.74%
Net Debt-205.63M USD
Net Debt/EBITDA3.94
Balance Sheet
Debt/Equity0.03
Current Ratio27.59
Quick Ratio26.94
Book Value/Sh2.10 USD
Cash/Share2.08 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)15.22 USD
Upside (mean)+169.2%
Target Range10.00 USD – 19.00 USD
10.00+169.2% to mean19.00
# Analysts9
Ownership
Shares Out.100.36M
Float67.76M
Insiders4.08%
Institutions80.08%
Short Interest
Short Ratio8.7d
Short % Float7.03%
Short % Out.6.78%
Shares Short6.81M
Short (prev mo.)6.01M
Technical
SMA 506.902 (-18.1%)
SMA 2005.861 (-3.5%)
Beta1.10
S&P 52W Chg16.45%
Avg Vol (30d)1.32M
Avg Vol (10d)1.56M
Technical Indicators
RSI (14)35.1
MACD-0.1851
MACD Signal-0.1495
MACD Hist.-0.0357
BB Upper6.996 USD
BB Middle6.338 USD
BB Lower5.681 USD
BB Width20.75%
ATR (14)0.4840 USD
Vol Ratio (20d)0.71x